Please amend the application filed on even date herewith prior to proceeding with its examination.

## IN THE CLAIMS

Please cancel claims 1-26, without prejudice or disclaimer.

- 27. (Currently Amended) An isolated composition consisting [essentially] of immunoglobulins as the active ingredient, [and] a polysaccharide selected from the group consisting of chitosanes and alginates, wherein the [molecules of polysaccharide] polysaccharidic molecules are neither chemically cross-linked to the immunoglobulins, nor to each other, in combination with suitable excipients and diluents.
- 28. (Previously Presented) The composition according to claim 27, wherein the immunoglobulins and the polysaccharides are associated by means of non-covalent links.
- 29. (Currently Amended) The composition according to claim 27, wherein the chitosanes are selected from the group consisting of chitosanes with a [low] molecular weight below 150,000 Da [and a high degree of deacetylation], methylglycolchitosane, and salts thereof.
- 30. (Previously Presented) The composition according to claim 29, wherein the chitosane is metilglicolchitosane or its salts.
- 31. (Previously Presented) The composition according to claim 27, wherein the alginates are selected from the group consisting of polymannuronic acid, alginic acid and its enzymatic fragments, and salts thereof.
- 32. (Previously Presented) The composition according to claim 27, wherein said immunoglobulins are selected from the group consisting of IgG, IgA, or their fragments F(ab')<sub>2</sub> or F(ab) or scFv.
  - 33. (Previously Presented) The composition according to claim 32, wherein

said immunoglobulins are IgG or their fragments F(ab')<sub>2</sub> or F(ab) or scFv.

- 34. (Previously Presented) The composition according to claim 27, wherein said immunoglobulins are specific for substances selected from the group consisting of toxins, infectious agents, hormones, enzymes, proenzymes, drugs of abuse, medicines, bioactive peptides, metabolites, physiologic precursors and their antigenic components.
- 35. (Previously Presented) The composition according to claim 34, wherein said toxins are of mycotic origin.
- 36. (Previously Presented) The composition according to claim 35, wherein said toxins are selected from the group consisting of ochratoxin, aflatoxin, zearalonon and fumonisine.
- 37. (Previously Presented) The composition according to claim 34, wherein the infectious agents are selected from the group consisting of Herpes simplex virus, cytomegalovirus (CMV), chickenpox virus, rubella virus, syncytial virus, respiratory virus, influenza virus, Epstein-Barr virus, Listeria monocytogenes, Salmonella thipy, Salmonella entheriditis, Salmonella paratiphy, Salmonella thiphymurium, Salmonella choleraensis, Clostridium tetani, Clostridium botulinum or Shigella, Candida albicans, and Toxoplasma gondii.
  - 38. (Cancelled)

- 39. (Cancelled)
- 40. (Previously Presented) The composition according to claim 34, wherein said drugs of abuse are selected from the group consisting of cocaine, heroin, lysergic acid or their derivatives.

- 41. (Previously Presented) The composition according to claim 34, wherein said medicines are selected from the group consisting of monensin, corticosteroids, antibiotics, anticoccidiostatics, antivirus, fungicides, chemiotherapic agents and sympathomimetic agents.
- 42. (Previously Presented) The composition according to claim 34, wherein said substances are selected from the following group:
  - a) somatostatin, glucagon cholecystoquinine and growth hormone;
  - b) parathormone and calcitonin;
  - c) pentagastrin;
  - d) thyroid hormone; and
  - e) prothrombin.
  - 43. (Cancelled)
  - 44. (Cancelled)
  - 45. (Cancelled)
  - 46. (Cancelled)
- 47. (Previously Presented) The composition according to claim 37, for the preparation of food additives.
- 48. (Previously Presented) The composition according to claim 27 for oral and transmucosal administration.
- 49. (Previously Presented) The composition according to claim 48, wherein said transmucosal administration is perlingual, rectal, vaginal, or buccal.
  - 50. (Cancelled)
  - 51. (Cancelled)